@article{oai:ngu.repo.nii.ac.jp:00000765,
 author = {齊藤, 久美子 and 酒井, 淳一 and 堀田, 芳弘},
 issue = {1},
 journal = {名古屋学院大学論集　人文・自然科学篇, THE NAGOYA GAKUIN DAIGAKU RONSHU; Journal of Nagoya Gakuin University; HUMANITIES and NATURAL SCIENCES},
 month = {Jul},
 note = {A new cardiotonic agent, SCH00013 (SCH), which was synthesized by Zenyaku Kogyo Company, Limited, exhibits cardiotonic effects by enhancing calcium sensitivity [1]. In this study, we examined the inotropic and chronotropic effects of SCH usin right atrial muscles extirpated from guinea pigs. Although 10 － 4 M SCH showed positive inotropic effects (50% of those of noradrenaline (NAd)), there was no increase in the heart rate. In addition, we measured changes in the left ventricular diastolic pressure (LVDP) and transient Ca 2 ＋ (TCa) signals in Fura-2-loaded Langendorff hearts. The administration of 10 －5 M SCH decreased the level of TCa, whereas 10 － 4 M SCH administration increased it. On the other hand, pimobendan (PIM), which is used as a drug for heart failure due to its calcium sensitivity-enhancing actions, decreased the level of TCa at 10 － 4 M despite an increase in contractility. This suggests that the mechanism of Ca 2＋ contractile protein system sensitivity differs between SCH and PIM. As SCH does not increase the heart rate in the presence of heart failure, it may protect the cardiac muscle.},
 pages = {23--33},
 title = {新規強心薬SCH00013のモルモット心臓に対する作用},
 volume = {53},
 year = {2016}
}